Nature Cancer

Article	Citations
Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis	360
Pan-cancer image-based detection of clinically actionable genetic alterations	356
Cancer vaccines: the next immunotherapy frontier	285
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab	259
Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer	255
Overcoming therapy resistance in EGFR-mutant lung cancer	217
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression	196
Cancer-associated fibroblasts in the single-cell era	184
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer	184
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors	183
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities	176
Fatty acid synthesis is required for breast cancer brain metastasis	168
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity	164
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma	161
Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology	160
Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity	155
The metabolic landscape of RAS-driven cancers from biology to therapy	154
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology	153
Artificial intelligence in histopathology: enhancing cancer research and clinical oncology	149
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells	145
Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity	132
The current paradigm and challenges ahead for the dormancy of disseminated tumor cells	132
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer	132
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy	125
Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial	124

Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas	123
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer	120
The cGAS–STING pathway and cancer	117
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy	116
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia	115
Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer	113
CD4+ T cells in cancer	113
Translational advances in pancreatic ductal adenocarcinoma therapy	112
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia	108
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma	107
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity	106
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study	105
The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response	103
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer	103
A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage	102
Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients	100
Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment	97
The immuno-oncological challenge of COVID-19	96
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort	95
Applications of organoids for cancer biology and precision medicine	94
Targeting public neoantigens for cancer immunotherapy	92
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis	91
Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism	90
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	89
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity	89
Emerging strategies for treating metastasis	86
Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in glioblastoma	86
SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer	85
Super enhancers define regulatory subtypes and cell identity in neuroblastoma	80
Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors	80
Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy	79
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia	77
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy	75
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets	75
Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors	75
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer	73
Age-associated mitochondrial DNA mutations cause metabolic remodeling that contributes to accelerated intestinal tumorigenesis	73
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer	73
Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGF-β2	72
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients	72
Dysregulation and therapeutic targeting of RNA splicing in cancer	72
Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis	71
Engineering-enhanced CAR T cells for improved cancer therapy	70
The present and future of PI3K inhibitors for cancer therapy	70
ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1	69
Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma	68
Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response	68
GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision	68
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer	67
Neutrophil oxidative stress mediates obesity-associated vascular dysfunction and metastatic transmigration	66

Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study	66
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets	63
Radiation exposure elicits a neutrophil-driven response in healthy lung tissue that enhances metastatic colonization	62
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment	62
The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer	61
Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma	60
Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression	59
Bystander T cells in cancer immunology and therapy	59
Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain	59
The status of tumor mutational burden and immunotherapy	59
Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment	57
Cancer cell plasticity during tumor progression, metastasis and response to therapy	57
Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer	57
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study	57
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors	54
Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer	54
The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome	53
Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors	52
cfDNA methylome profiling for detection and subtyping of small cell lung cancers	52
Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment	51
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology	51
Advances in antibody-based therapy in oncology	51
TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer	51
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity	49
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer	49
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes	49
A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance	49
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma	48
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia	48
Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells	47
Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy	47
Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	47
Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs	47
An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognostication	47
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms	46
Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis	46
Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities	46
Accelerating precision medicine in metastatic prostate cancer	45
Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma	45
A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types	45
Advancing Cancer Therapy	44
KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming	43
The deubiquitinase USP25 supports colonic inflammation and bacterial infection and promotes colorectal cancer	43
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy	43
The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription	43
Illuminating the noncoding genome in cancer	43
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response	43
Moving pan-cancer studies from basic research toward the clinic	43
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect	42
APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis	42
Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response	42
GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity	42
The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets	40
Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors	39
A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling	39
Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways	39
The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations	39
Cancer-associated fibroblasts employ NUFIP1-dependent autophagy to secrete nucleosides and support pancreatic tumor growth	38
Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer	38
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	38
Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade	38
Metabolic adaptation of acute lymphoblastic leukemia to the central nervous system microenvironment depends on stearoyl-CoA desaturase	38
Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy	37
Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress	37
Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia	37
ALK-positive lung cancer: a moving target	37
Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia	37
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance	37
Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues	37
Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression	36
Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors	36
Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice	36
MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis	36
The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer	34
Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia	34
Pharmacological disruption of the MTDH–SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer	33
Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting	33
Clinical and translational advances in ovarian cancer therapy	32
A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC	32
Discovery through clinical sequencing in oncology	32

LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2–cFLIP–NF-κB signaling axis	32
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse	31
Deep learning links histology, molecular signatures and prognosis in cancer	31
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders	31
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity	31
The challenges of implementing low-dose computed tomography for lung cancer screening in low- and middle-income countries	31
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1	30
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	30
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	30
SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes	29
High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers	29
LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer	29
Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer	29
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling	29
Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis	29
Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes	28
Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity	28
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	28
Advances in ovarian cancer, from biology to treatment	27
Disrupting the phase separation of KAT8–IRF1 diminishes PD-L1 expression and promotes antitumor immunity	27